A practical reference on prothymosin alpha: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-31 and is reviewed periodically as new material appears.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | 28 residues; not a small-molecule compound |
| Molecular mass | About 3,106 Da | Monoisotopic mass of the unmodified chain |
| N-terminal group | Acetylated serine | Present in both native and synthetic forms |
| Secondary structure | Disulfide-constrained loop | One bridge between two cysteine residues |
| Typical source | Solid-phase synthesis | Early isolates came from bovine thymus extracts |
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
=== Structure === Unlike traditionally prepared food, the variety of food that can be manufactured using 3D printing is limited by the physical characteristics of the materials. Food materials are generally much softer than the weakest plastic used in 3D printing, making the printed structures very fragile. So far, most studies use trial and error as an approach to overcoming this challenge, but scientists are working on developing new methods that are able to predict the behavior of different materials during the printing process. These methods are developed by analyzing the rheological properties of the materials and their relation to the printing stability.
== Structure == Free fatty acid receptor 3 is a member of the G protein-coupled receptor (GPCR) superfamily, characterized by its seven transmembrane alpha-helices. FFAR3 shares significant sequence similarity with FFAR2 but exhibits distinct structural features that influence its ligand specificity and signaling. The receptor's orthosteric binding pocket is formed by transmembrane helices 3, 4, and 5, with key conserved residues such as Arg-185 (5.39), Arg-255 (7.35), His-140 (4.56), and His-242 (6.55) contributing to the binding and recognition of short-chain fatty acids (SCFAs) like acetate, propionate, and butyrate. Notably, FFAR3's binding cavity is more hydrophilic compared to its close relative FFAR2, which affects its ligand interactions. The second extracellular loop is important in modulating ligand selectivity and receptor activation. Additionally, the presence of a His-45 (2.40) is predicted to coordinate allosteric modulators. The human FFAR3 and FFAR2 proteins consist of 346 and 330 amino acids, respectively, and share about a 40% amino acid sequence homology. The two FFARs have been found to form a heteromer complex (i.e., FFAR3 and FFAR2 bind to each other and are activated together by a SC-FA). When stimulated by a SC-FA, the cells expressing both FFAR3 and FFAR2 may form this heterodimer and thereby activate cell signaling pathways and mount responses that differ from those of cells expressing only one of these FFARs.
=== Ligand removal === In many cases, as in various high-temperature catalytic applications of Au, the removal of the capping ligands produces more desirable physicochemical properties. The removal of ligands from colloidal gold while maintaining a relatively constant number of Au atoms per Au NP can be difficult due to the tendency for these bare clusters to aggregate. The removal of ligands is partially achievable by simply washing away all excess capping ligands, though this method is ineffective in removing all capping ligand. More often ligand removal achieved under high temperature or light ablation followed by washing. Alternatively, the ligands can be electrochemically etched off.
== War period, 1938–1945 == When the committee was outlawed in September 1937, six of its members were deported, its president Amin al-Husayni managed to escape arrest and went into exile in Beirut. Jamal al-Husayni escaped to Syria. Three other members were deported to the Seychelles, and other members moved into voluntary exile in neighbouring countries. Al-Hadi, who was out of the country at the time, was not allowed to return. Membership of the outlawed committee had dwindled to Jamal al-Husayni (acting chairperson), Husayn al-Khalidi (secretary), Ahmed Hilmi Pasha and Emil Ghuri. For all practical purposes, the committee ceased to exist, however, this brought little change in the structure of Arab political life and the Palestinian revolt continued. With the indications of a new European war on the horizon, and in an endeavor to resolve the inter-communal issues in Palestine, the British government proposed in late 1938 a conference in London of the two Palestinian communities. Some Arab leaders welcomed the proposed London Conference but indicated that the British would need to deal with the disbanded Arab Higher Committee and with Amin al-Husayni. On 23 November 1938, the Colonial Secretary, Malcolm MacDonald, repeated his refusal to allow Amin al-Husayni to be a delegate, but was willing to allow the five Palestinian leaders held in the Seychelles to take part in the conference.
Sources: en.wikipedia.org
A rotary lathe in which the wood is turned against a very sharp blade and peeled off in one continuous or semi-continuous roll. Rotary-cut veneer is mainly used for plywood, as the appearance is not desirable because the veneer is cut concentric to the growth rings. A slicing machine in which the flitch or piece of log is raised and lowered against the blade and slices of the log are made. This yields veneer that looks like sawn pieces of wood, cut across the growth rings; such veneer is referred to as "crown cut". A half-round lathe in which the log or piece of log can be turned and moved in such a way as to expose the most interesting parts of the grain, creating a more textured feel and appearance; such veneer is commonly referred to as "rift cut". Each slicing process gives a very distinctive type of grain, depending upon the tree species. In any of the veneer-slicing methods, when the veneer is sliced, a distortion of the grain occurs. As it hits the wood, the knife blade creates a "loose" side where the cells have been opened up by the blade, and a "tight" side. Veneers are cut as thin as 0.64 mm (1⁄40 in). Depending on the cutting process used by the veneer manufacturer, very little wood is wasted by the saw blade thickness, known as the saw kerf. Some manufacturers use a very wide knife to slice off the thin veneer pieces. In this process, none of the wood is wasted. The slices of veneer are always kept in the order in which they are cut from the log and are often sold this way. Historically, veneers were also sawn in approximately 3 mm (1⁄8 in) thick layers.
=== Energy use === Early assessments of energy use in grey matter signaling suggested that 95% was attributed to neurons and 5% to astrocytes. However, after discovering that action potentials were more efficient than initially believed, the energy budget was adjusted: 70% for dendrites, 15% for axons, and 7% for astrocytes. Previous accounts assumed that astrocytes captured synaptic K+ solely via Kir4.1 channels. However, it's now understood they also utilize Na+/K+ ATPase. Factoring in this active buffering, astrocytic energy demand increases by >200%. This is supported by 3D neuropil reconstructions indicating similar mitochondrial densities in both cell types, as well as cell-specific transcriptomic and proteomic data, and tricarboxylic acid cycle rates. Therefore "Gram-per-gram, astrocytes turn out to be as expensive as neurons".
=== Sagan's finer classification === In 1973, Carl Sagan discovered Kardashev's work on the classification of civilizations. He found that the differences between the types Kardashev identified were so great that they did not allow for the best possible modeling of the evolution of civilizations. Consequently, Sagan proposed a more refined classification, still based on Kardashev's types, but integrating intermediate levels using the following logarithmic interpolation formula:
== Management == Initial therapy of the major rheumatological diseases is with analgesics, such as paracetamol and non-steroidal anti-inflammatory drugs (NSAIDs). Steroids, especially glucocorticoids, and stronger analgesics are often required for more severe cases.
== Selected bibliography == Daly, Marie M.; Mirsky, A.E. (June 1949). "Chromatography of Purines and Pyrimidines on Starch Columns". Journal of Biological Chemistry. 179 (2): 981–982. doi:10.1016/S0021-9258(19)51291-1. PMID 18150028. Daly, M.M.; Allfrey, V.G.; Mirsky, A.E. (May 20, 1950). "Purine and Pyrimidine Contents of Some Desoxypentose Nucleic Acids" (PDF). Journal of General Physiology. 33 (5): 497–510. doi:10.1085/jgp.33.5.497. PMC 2147206. PMID 15422104. Daly, Marie; Mirsky, A.E.; Ris, Hans (March 20, 1951). "The Amino Acid Composition and Some Properties of Histones" (PDF). The Journal of General Physiology. 34 (4): 439–450. doi:10.1085/jgp.34.4.439. PMC 2147226. PMID 14824510. Daly, Marie M.; Mirsky, A.E. (November 1952). "Formation of Protein in the Pancreas". Journal of General Physiology. 36 (2): 243–254. doi:10.1085/jgp.36.2.243. PMC 2147369. PMID 13011280. Daly, Marie M.; Allfrey, V.G.; Mirsky, A.E. (November 1952). "Uptake of Glycine-N15 by Components of Cell Nuclei" (PDF). Journal of General Physiology. 36 (2): 173–179. doi:10.1085/jgp.36.2.173. PMC 2147362. PMID 13011275. Allfrey, V.; Daly, M.M.; Mirsky, A.E. (November 20, 1953). "Synthesis of protein in the pancreas. II. The role of ribonucleoprotein in protein synthesis". Journal of General Physiology. 37 (2): 157–175. doi:10.1085/jgp.37.2.157. PMC 214743. PMID 13109153. Mirsky, A.E.; Allfrey, V.G.; Daly, M.M. (September 1954). "The Uptake of N15-Labelled Glycine by Liver Proteins". Journal of Histochemistry and Cytochemistry. 2 (5): 376–377. doi:10.1177/2.5.376. PMID 13192326. S2CID 40223958.
Sources: en.wikipedia.org
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.
The single bridge between two cysteine residues holds the chain in a folded loop that influences its shape and its behavior in solution. Loss of the bridge through reduction or oxidation shifts chromatographic retention and is tracked during stability work.
It is a defined 28-residue sequence derived from a larger precursor, whereas many other thymic preparations are mixtures of several polypeptides. Its acetylated amino terminus and single disulfide bridge distinguish it chemically from unrelated thymic extracts.
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.